In San Francisco, industrial biotechnology startup Bota Bio has raised $100 million in an oversubscribed Series B financing. Founded in 2019, Bota Bio has developed its Bota Freeway platform to integrate “advanced digital tools” with lab automation.
“Most traditional manufacturing comes with a high environmental cost. We are building Bota Bio to innovate solutions that help manufacturers in all industries leverage the power of biology to accelerate the design and scale-up of high-performance products using sustainable processes,” says Cheryl Cui, Ph.D., co-founder and CEO, Bota Bio. “We are empowering a diverse global client base from different industries to develop bio-based alternatives to traditional ingredients. We are thrilled to have this syndicate of renowned investors support our efforts in transforming global manufacturing.”
The series was led by Sequoia Capital China. Previous investors Matrix Partners China, Source Code Capital, Sherpa Healthcare Partners, and 5Y Capital also participated. The financing brings Bota Bio’s total funding to $145 million. The funds will be used to expand Bota Bio’s operations and build out its lab-to-pilot scale platform.